By the time a pathologist renders a cancer diagnosis, they may have already examined thousands of cells under a microscope, cross-referenced clinical data, and consulted colleagues across specialties. It is a meticulous, deeply human process. Now, artificial intelligence is beginning to join that workflow, not to replace the pathologist, but to sharpen the lens through which they see.
Digital pathology, the practice of converting glass slides into high-resolution digital images for analysis and storage, has been gaining traction for years. But the introduction of AI-powered tools into this space is accelerating a transformation that promises faster diagnoses, fewer errors, and a more equitable distribution of expert-level care. The implications for laboratories, clinicians, and patients alike are profound.
What Is Digital Pathology and Why Does It Matter?
Traditional pathology relies on physical glass slides that must be stained, prepared, and viewed through a microscope. This process, while effective, is constrained by geography, time, and human bandwidth. A single pathologist can only review so many slides in a day, and the global shortage of trained pathologists makes this bottleneck even more pronounced.
Digital pathology converts these slides into whole slide images using specialized scanning equipment. Once digitized, slides can be stored, shared, annotated, and analyzed remotely. Pathologists in different cities or countries can collaborate in real time. Archived cases can be revisited without physically locating a glass slide that may have degraded over decades.
When AI enters this picture, the entire system gains a new dimension of capability. Machine learning algorithms trained on hundreds of thousands of annotated slides can identify cellular patterns, flag anomalies, and even quantify features that are difficult for the human eye to measure consistently. What was once a purely subjective art form begins to incorporate objective, reproducible data points.
How AI Is Being Applied in Pathology Labs
The applications of AI in digital pathology are broad and continue to evolve rapidly. Some of the most impactful use cases currently in practice include the following.
Cancer Detection and Grading
- AI models can detect and classify tumors in tissue samples with a level of precision that rivals, and in some studies exceeds, that of experienced pathologists
- Algorithms trained specifically on prostate, breast, lung, and colorectal cancers have demonstrated strong performance in identifying malignant cells and grading tumor severity
- AI tools can help reduce the variability that naturally occurs when different pathologists grade the same slide, a common challenge in oncology
Biomarker Quantification
- Certain treatment decisions depend on accurately measuring biomarkers such as PD-L1 expression or HER2 amplification
- AI-powered image analysis can quantify these markers far more consistently than manual counting, reducing interpretive errors that could affect treatment selection
Workflow Triage and Prioritization
- Laboratories that receive hundreds of slides daily face real capacity challenges
- AI can pre-screen slides and flag high-priority cases for immediate review, ensuring that urgent diagnoses like aggressive malignancies are not buried in routine workloads
Quality Control
- AI tools can detect technical slide preparation issues such as poor staining, blurring, or tissue folding before a pathologist wastes time reviewing an inadequate sample
- This kind of automated quality assurance reduces rework and improves overall throughput
Rare Disease Identification
- Certain conditions are so uncommon that even experienced pathologists may encounter them only a handful of times in their careers
- AI systems trained on large, curated datasets can recognize patterns associated with rare diseases that a clinician might not immediately identify from memory alone
Companies Leading the Charge
A growing ecosystem of companies is developing and deploying AI tools specifically designed for pathology labs. Several have already earned regulatory approvals and are operating in active clinical environments.
- NovoPath is a laboratory information system software provider what works primarily with anatomic pathology labs. As these labs adopt more digital tools, NovoPath is leading the way in laboratory management software for digital pathology.
- Paige AI is one of the most prominent names in the field. The company received FDA authorization for its prostate cancer detection algorithm, making it one of the first AI tools of its kind to gain regulatory clearance in the United States. Paige has since expanded its product portfolio to include solutions for breast, lung, and colon cancers, and has formed partnerships with major academic medical centers to deploy its technology in clinical settings.
- PathAI focuses on developing AI-powered tools for both clinical diagnosis and drug development. The company works closely with pharmaceutical companies to use digital pathology data in clinical trials, helping researchers better understand how treatments are affecting tissue at a cellular level. PathAI has also invested heavily in building large, diverse datasets to ensure its models perform equitably across different patient populations.
- Owkin takes a federated learning approach to AI in healthcare, allowing hospitals and research institutions to collaborate on model training without sharing sensitive patient data. The company has applied this model to pathology, enabling its algorithms to learn from slide data across multiple sites simultaneously, which produces more robust and generalizable results.
- Lunit is a South Korean company that has built a suite of AI-powered pathology tools with a particular focus on cancer diagnostics. Its Lunit SCOPE product analyzes tumor microenvironments and provides quantitative insights into how a tumor is interacting with the immune system, information that is increasingly critical in the era of immunotherapy.
- Aiforia Technologies offers a platform that allows pathologists and researchers to train their own AI models without requiring deep programming expertise. This democratizes access to machine learning in pathology, enabling smaller labs and academic institutions to build customized tools tailored to their specific needs.
- Ibex Medical Analytics has developed a clinical-grade AI system called Galen that analyzes pathology slides for prostate and breast cancer detection. The system is designed to integrate directly into existing laboratory information systems, minimizing workflow disruption.
- Hologic, a larger medical device company, has also moved into AI-assisted pathology through its acquisitions and partnerships, recognizing the commercial potential of combining digital imaging with intelligent software in the cervical cancer screening space.
These companies represent a cross-section of approaches, ranging from narrow, regulatory-cleared tools targeting specific cancer types to broad platforms that can be customized across use cases. Together, they are building the infrastructure for an AI-enabled pathology future.
Regulatory Landscape and the Road to Adoption
The path to clinical adoption involves navigating a complex regulatory environment. In the United States, the FDA classifies many AI-powered pathology tools as Software as a Medical Device, and companies must demonstrate both safety and clinical utility before receiving authorization to deploy in clinical settings.
Several tools have already cleared this bar, and the FDA has demonstrated a growing willingness to engage constructively with AI-based diagnostic tools. In Europe, the CE marking process serves a similar function, and regulatory bodies there have also approved a number of AI pathology products.
Despite this progress, adoption in routine clinical practice remains uneven. Many hospitals and health systems are still in the evaluation phase, piloting tools in research or quality assurance contexts before committing to full clinical integration. Pathologists themselves vary in their enthusiasm, with some eager to embrace AI assistance and others cautious about over-reliance on systems whose inner workings are not always transparent.
Interoperability is another practical challenge. Most labs operate a patchwork of legacy systems, and integrating new AI tools requires careful attention to data formats, file compatibility, and regulatory compliance at every connection point.
What This Means for Broader Healthcare
The ripple effects of AI in pathology extend well beyond the lab. When diagnoses become faster and more accurate, the entire clinical pipeline accelerates. Patients spend less time in diagnostic limbo. Oncologists receive richer, more quantitative data to inform treatment planning. Pharmaceutical companies gain better tools for stratifying patients in clinical trials. And healthcare systems find new opportunities to manage costs while maintaining or improving quality.
Reducing Diagnostic Disparities
One of the most compelling arguments for AI in pathology is its potential to reduce geographic and economic disparities in diagnostic quality. In many parts of the world, including rural regions of the United States, trained pathologists are scarce. A community hospital in a medically underserved area may have limited access to subspecialty expertise in areas like neuropathology or dermatopathology. AI tools, deployed via cloud-based platforms, can bring expert-level pattern recognition to any lab that has a scanner and an internet connection.
Supporting the Overburdened Pathologist
The global pathology workforce is under significant strain. Demand for diagnostic services is rising as the population ages and cancer screening programs expand, yet the pipeline of newly trained pathologists is not keeping pace. AI tools that handle routine screening tasks, flag priority cases, and automate quantitative measurements can meaningfully reduce cognitive burden and allow pathologists to focus their expertise where it matters most.
Accelerating Drug Discovery
In pharmaceutical research, pathology data is a cornerstone of understanding how candidate drugs affect tissue. AI-powered analysis of histopathology slides can accelerate preclinical studies, help identify patient populations most likely to respond to a therapy, and provide continuous, quantitative monitoring of treatment response during clinical trials. This could shorten drug development timelines, which currently average more than a decade from discovery to approval.
Shifting the Role of the Pathologist
It is worth addressing a concern that many in the field raise directly: will AI replace pathologists? The evidence and expert consensus strongly suggest it will not. What AI is more likely to do is fundamentally reshape the role. The pathologist of the future will be less of a slide reviewer and more of a data interpreter, someone who synthesizes AI-generated insights with clinical context, patient history, and molecular data to deliver a holistic diagnostic picture.
This is already beginning to happen. Some pathologists are working alongside AI tools daily, using them as a second read on difficult cases or as a triage mechanism for large case volumes. The relationship is collaborative, not competitive.
Challenges That Must Be Addressed
For all its promise, AI in digital pathology is not without meaningful challenges that the field must continue to grapple with honestly.
- Bias in training data: AI models are only as good as the data they learn from. If training datasets underrepresent certain demographic groups, the resulting algorithms may perform poorly for those populations, potentially worsening existing health disparities rather than reducing them
- Transparency and explainability: Many AI systems function as black boxes, producing outputs without clearly articulating the reasoning behind them. This creates tension with the clinical tradition of evidence-based reasoning and makes it difficult for pathologists to evaluate when they should trust an AI recommendation and when they should override it
- Validation across settings: A model that performs well in an academic medical center with standardized tissue processing protocols may behave differently in a community hospital with different equipment and procedures
- Reimbursement: Healthcare systems in most countries have not yet established clear reimbursement pathways for AI-assisted pathology, creating a financial barrier to adoption even when the clinical case is strong
Looking Ahead
The integration of AI into digital pathology is not a future possibility. It is happening now, in real laboratories, influencing real diagnoses. What lies ahead is a period of maturation, in which early tools are refined, evidence accumulates, regulatory frameworks solidify, and workflows adapt to accommodate a new generation of intelligent assistants.
The stakes are high. Pathology sits at the foundation of medicine. Nearly every significant clinical decision, whether to initiate chemotherapy, proceed with surgery, or select a targeted therapy, rests on a pathological diagnosis. Making that foundation more accurate, more consistent, and more accessible is not merely a technical achievement. It is a meaningful advance for patients everywhere.
The microscope changed pathology in the nineteenth century. Digital imaging changed it again at the turn of the twenty-first. Artificial intelligence may well represent the most significant transformation yet, one that does not diminish the expertise of the pathologist but extends it far beyond the walls of any single laboratory.
